Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders - PubMed (original) (raw)
Multicenter Study
. 2001 Feb 1;19(3):772-8.
doi: 10.1200/JCO.2001.19.3.772.
N Dhedin, M F Mamzer Bruneel, S Choquet, O Hermine, R Porcher, S Nguyen Quoc, F Davi, F Charlotte, R Dorent, B Barrou, J P Vernant, M Raphael, V Levy
Affiliations
- PMID: 11157030
- DOI: 10.1200/JCO.2001.19.3.772
Multicenter Study
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders
V Leblond et al. J Clin Oncol. 2001.
Abstract
Purpose: Prognostic studies of posttransplantation lymphoproliferative disorders (PTLDs) are hindered by the small number of cases at each transplant center. We analyzed prognostic factors and long-term outcome according to clinical manifestations, pathologic features, and treatment and investigated the prognostic value of the non-Hodgkin's lymphoma International Prognostic Index (IPI) in 61 patients with PTLD.
Patients and methods: We studied 61 patients in two institutions who developed PTLD and analyzed factors influencing the complete remission and survival rates.
Results: In univariate analysis, factors predictive of failure to achieve complete remission were performance status (PS) > or = (P =.0001) and nondetection of Epstein-Barr virus (EBV) in the tumor (P =.01). Only a negative link with PS > or = 2 was observed in multivariate analysis. In univariate analysis, factors predictive of lower survival were PS > or = 2, the number of sites (one v > one), primary CNS localization, T-cell origin, monoclonality, nondetection of EBV, and treatment with chemotherapy. The IPI failed to identify a patient subgroup with better survival and was less predictive of the response rate than was a specific index using two risk factors (PS and number of involved sites), which defined three groups of patients: low-risk patients whose median survival time has not yet been reached, intermediate-risk patients with a median survival time of 34 months, and high-risk patients with a median survival time of 1 month.
Conclusion: PS and the number of involved sites defined three risk groups in our population. The value of these prognostic factors needs to be confirmed in larger cohorts of patients treated in prospective multicenter studies.
Similar articles
- Identification of prognostic factors in post-transplant lymphoproliferative disorders.
Choquet S, Mamzer BM, Hermine O, Porcher R, Nguyen QS, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V, Leblond V. Choquet S, et al. Recent Results Cancer Res. 2002;159:67-80. doi: 10.1007/978-3-642-56352-2_9. Recent Results Cancer Res. 2002. PMID: 11785846 - Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E; Cooperative Study Group on PTLDs. Muti G, et al. Haematologica. 2002 Jan;87(1):67-77. Haematologica. 2002. PMID: 11801467 - Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Knight JS, et al. J Clin Oncol. 2009 Jul 10;27(20):3354-62. doi: 10.1200/JCO.2008.20.0857. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451438 - New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients.
Preiksaitis JK. Preiksaitis JK. Clin Infect Dis. 2004 Oct 1;39(7):1016-23. doi: 10.1086/424447. Epub 2004 Sep 13. Clin Infect Dis. 2004. PMID: 15472855 Review. - [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
Franco A, Jiménez L, Aranda I, Alvarez L, González M, Rocamora N, Olivares J. Franco A, et al. Nefrologia. 2002;22(5):463-9. Nefrologia. 2002. PMID: 12497748 Review. Spanish.
Cited by
- Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?
Morscio J, Dierickx D, Tousseyn T. Morscio J, et al. Clin Dev Immunol. 2013;2013:150835. doi: 10.1155/2013/150835. Epub 2013 Apr 14. Clin Dev Immunol. 2013. PMID: 23690819 Free PMC article. Review. - Survival of Post-Transplant Lymphoproliferative Disorder after Kidney Transplantation in Patients under Rapamycin Treatment.
Ashrafi F, Shahidi S, Mehrzad V, Mortazavi M, Hosseini SF. Ashrafi F, et al. Int J Hematol Oncol Stem Cell Res. 2021 Oct 1;15(4):239-248. doi: 10.18502/ijhoscr.v15i4.7479. Int J Hematol Oncol Stem Cell Res. 2021. PMID: 35291663 Free PMC article. - Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases.
Trappe R, Zimmermann H, Fink S, Reinke P, Dreyling M, Pascher A, Lehmkuhl H, Gärtner B, Anagnostopoulos I, Riess H. Trappe R, et al. Haematologica. 2011 Jul;96(7):1067-71. doi: 10.3324/haematol.2010.039214. Haematologica. 2011. PMID: 21719885 Free PMC article. - Large granular lymphocytosis after transplantation.
Qiu ZY, Tian GY, Zhang Z, Zhang YQ, Xu W, Li JY. Qiu ZY, et al. Oncotarget. 2017 Sep 18;8(46):81697-81708. doi: 10.18632/oncotarget.21009. eCollection 2017 Oct 6. Oncotarget. 2017. PMID: 29113425 Free PMC article. Review. - Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders.
Margolskee E, Jobanputra V, Jain P, Chen J, Ganapathi K, Nahum O, Levy B, Morscio J, Murty V, Tousseyn T, Alobeid B, Mansukhani M, Bhagat G. Margolskee E, et al. Oncotarget. 2016 Jun 21;7(25):37636-37648. doi: 10.18632/oncotarget.9400. Oncotarget. 2016. PMID: 27203213 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical